Navigation Links
Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate

-Trial to Examine New Therapeutic Platform in Patients with Cystoid Macular


SUNNYVALE, Calif., Aug. 5 /PRNewswire/ -- Icon Bioscience, Inc., (IBI), a privately held ophthalmic pharmaceutical company, announced today that enrollment has been completed in its Phase I clinical trial to assess the safety and efficacy of its lead product, IBI-20089, in patients with cystoid macular edema. This multi-site trial enrolled patients with cystoid macular edema associated with retinal vein occlusion and post operative cataract surgery.

IBI-20089 is a novel drug product based on IBI's proprietary Verisome(TM) drug delivery platform technology, which is optimally suited for application in the ophthalmic market. IBI-20089 is designed to last up to one year with a single intravitreal injection. It uniquely provides physicians the flexibility to tailor the duration of effect for a particular patient. IBI- 20089 is administered as a standard intravitreal injection without the need for additional devices or surgical procedures.

"We are pleased to have reached this important milestone. Our preliminary data confirms the safety and efficacy of our lead product, IBI-20089, as well as the versatility and flexibility of our underlying Verisome(TM) drug delivery technology," said Vernon G. Wong, MD, Founder of Icon Bioscience, Inc. "We believe IBI is creating the future standard of ophthalmic care as evidenced by the development of IBI-20089, the first of many products already in development based on the Verisome(TM) technology."

About Icon Bioscience, Inc.

Icon Bioscience, Inc. (IBI) is a privately held company focused on the development and commercialization of novel ophthalmic pharmaceuticals, based on its proprietary Verisome(TM) drug delivery platform. The Verisome(TM) drug delivery technology encompasses over twenty related but distinct novel and proprietary drug delivery systems optimally suited for application in the ophthalmic market. The nature of ophthalmic disease and the unique anatomical and physiological features of the eye, combined with the extreme fragility of the eye, dictate that identifying the correct pharmaceutical agent for a specific disease state represents only half the solution. The pharmaceutical agent must be delivered in a manner that maximizes clinical efficacy while minimizing costs and adverse effects. IBI's lead product, IBI-20089, is in Phase I clinical trials for the treatment of cystoid macular edema.

Contact: Icon Bioscience, Inc.

William S. (Sandy) White

Phone: 408-734-8188 Ext. 14


SOURCE Icon Bioscience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th ... Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised ... have been wounded in battle and their families. Venture Construction Group is a 2016 ...
(Date:6/24/2016)... Gilbert, Arizona (PRWEB) , ... June 24, 2016 ... ... Gilbert-based practice, is supporting the upcoming 2016 Miss Arizona pageant as its official ... primarily serves Scottsdale, Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says ...
Breaking Medicine News(10 mins):